Desjardins Global Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Desjardins Global Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$121K	Sell	1,256 -56	-4%	-$4.95K	0.01%	433
2023 Q3	$116K	Buy	1,312 +457	+53%	+$40.7K	0.01%	446
2023 Q2	$74.1K	Buy	855 +89	+12%	+$8.38K	0.01%	513
2023 Q1	$74K	Sell	766 -44	-5%	-$4.56K	0.01%	493
2022 Q4	$83K	Sell	810 -3	-0.4%	-$282	0.01%	408
2022 Q3	$68K	Sell	813 -2	-0.2%	-$178	0.01%	411
2022 Q2	$67K	Buy	815 +246	+43%	+$19.6K	0.01%	407
2022 Q1	$43K	Sell	569 -34	-6%	-$2.85K	﹤0.01%	427
2021 Q4	$53K	Buy	+603	New	+$49.8K	﹤0.01%	428

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Desjardins Global Asset Management's BMRN Position: Q4 2023 in Review

Desjardins Global Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 4.3% in Q4 2023, selling an estimated $4.95K and leaving 1,256 shares worth $121K. The position accounts for 0.01% of the portfolio, ranked #433.

Desjardins Global Asset Management first reported a position in BMRN in Q4 2021 and has held it in 9 quarters since. 547 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

Desjardins Global Asset Management held 1,256 shares of BioMarin Pharmaceuticals worth $121K as of Q4 2023.
Desjardins Global Asset Management sold 56 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $4.95K.
BioMarin Pharmaceuticals made up 0.01% of Desjardins Global Asset Management's portfolio in Q4 2023, its #433 holding.
Desjardins Global Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2021 and has held it in 9 quarters since.
547 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on Desjardins Global Asset Management's 13F filing for Q4 2023, filed 30 Jan 2024.